EN
营业咨询
中国：
Email: marketing@medicilon.com.cn
营业咨询专线：400-780-8018
（仅限效劳咨询 ，其他事宜请拨打川沙总部电话）
川沙总部电话: +86 (21) 5859-1500
外洋：
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com
由于KRAS突变的高爆发率及其在启动和维持肿瘤生长中的主要性 ，靶向 KRAS便成为一种理想的治疗战略。
Targeting KRAS is a desirable strategy because of the high prevalence of KRAS mutations and its importance in initiating and sustaining tumor growth.
KRAS是RAS家族中最常见突变的成员 ， KRAS突变在多种恶性肿瘤中以差别的爆发率泛起,其发病率以胰腺癌最高 ，其次是结直肠癌、非小细胞肺癌和胆管癌。
KRAS is the most commonly mutated member of the Ras family,KRAS mutations are seen in a variety of malignancies at different rates,its incidence is highest in pancreatic cancers,followed by coleractal cancer,NSCLC and colangiocarcinoma.
KRAS突变谱在差别癌症类型之间保存显著差别 ，98%的KRAS突变位于G12、G13或 Q61。
The profile of KRAS mutations differ significantly among diverse cancer types.98% of KRAS mutations are found at G12,G13,or Q61.
KRAS突变爆发在许多具有差别突变频率的癌症中 ，但突变亚型也保存很大差别� ；颊叨訩RAS G12抑制剂的反应差别 ，体现保存内在耐药性 ，以是需要一连探索耐药性 ，以确定临床试验中指示适当人群和肿瘤类型的生物标记物。
KRAS mutations occur in many cancers with different mutation frequencies, but there is also a large variation in mutation subtypes. The response to KRAS G12c inhibitors in patients is different, implicating the existence of resistance. Exploration of resistance should be conducted to identify biomarkers that indicate the appropriate population and tumor type in the clinical trial.
相关新闻川沙总部
地点: 上海市浦东新区川亨衢585号
邮编: 201299
电话: +86 (21) 5859-1500（总机）
传真: +86 (21) 5859-6369
外洋：
Email:?marketing@medicilon.com
Tel: +1 (617) 888-9294(U.S.)
Tel: 0044 7790 816 954 (Europe)
Tel: +82 70-8269-5849 (Korea)
Tel: +81 80-4421-6898 (Japan)
